Ahrang Jung1,2, Matthew E Nielsen1,3, Jamie L Crandell2, Mary H Palmer2, Sophia K Smith4, Ashley Leak Bryant1,2, Deborah K Mayer1,2. 1. Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 2. School of Nursing, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 3. School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 4. School of Nursing, Duke University, Durham, NC, USA.
Abstract
OBJECTIVE: To examine the effect of non-muscle-invasive bladder cancer (NMIBC) diagnosis and treatment on survivors' quality of life (QoL). PATIENTS AND METHODS: Of the 5979 patients with NMIBC diagnosed between 2010 and 2014 in North Carolina, 2000 patients were randomly selected to be invited to enroll in this cross-sectional study. Data were collected by postal mail survey. The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core (QLQ-C30) and the NMIBC-specific module were included in the survey to measure QoL. Descriptive statistics, t-tests, anova, and Pearson's correlation were used to describe demographics and to assess how QoL varied by sex, cancer stage, time since diagnosis, and treatment. RESULTS: A total of 398 survivors returned questionnaires (response rate: 23.6%). The mean QoL score for QLQ-C30 (range 0-100, higher = better QoL in all domains but symptoms) for global health status was 73.6, function domain scores ranged from 83.9 to 86.5, and scores for the top five symptoms (insomnia, fatigue, dyspnoea, pain, and financial difficulties) ranged from 14.1 to 24.3. The lowest NMIBC-specific QoL domain was sexual issues including sexual function, enjoyment, problems, and intimacy. Women had worse bowel problems, sexual function, and sexual enjoyment than men but better sexual intimacy and fewer concerns about contaminating their partner. Stage Ta had the highest global health status, followed by T1 and Tis. QoL did not vary by time since diagnosis except for sexual function. The cystectomy group (n = 21) had worse QoL in sexual function, discomfort with sexual intimacy, sexual enjoyment, and male sexual problems than the non-cystectomy group (n = 336). CONCLUSION: Survivors of NMIBC face a unique burden associated with their diagnosis and the often-lifelong surveillance and treatment regimens. The finding has important implications for the design of tailored supportive care interventions to improve QoL for NMIBC survivors.
OBJECTIVE: To examine the effect of non-muscle-invasive bladder cancer (NMIBC) diagnosis and treatment on survivors' quality of life (QoL). PATIENTS AND METHODS: Of the 5979 patients with NMIBC diagnosed between 2010 and 2014 in North Carolina, 2000 patients were randomly selected to be invited to enroll in this cross-sectional study. Data were collected by postal mail survey. The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core (QLQ-C30) and the NMIBC-specific module were included in the survey to measure QoL. Descriptive statistics, t-tests, anova, and Pearson's correlation were used to describe demographics and to assess how QoL varied by sex, cancer stage, time since diagnosis, and treatment. RESULTS: A total of 398 survivors returned questionnaires (response rate: 23.6%). The mean QoL score for QLQ-C30 (range 0-100, higher = better QoL in all domains but symptoms) for global health status was 73.6, function domain scores ranged from 83.9 to 86.5, and scores for the top five symptoms (insomnia, fatigue, dyspnoea, pain, and financial difficulties) ranged from 14.1 to 24.3. The lowest NMIBC-specific QoL domain was sexual issues including sexual function, enjoyment, problems, and intimacy. Women had worse bowel problems, sexual function, and sexual enjoyment than men but better sexual intimacy and fewer concerns about contaminating their partner. Stage Ta had the highest global health status, followed by T1 and Tis. QoL did not vary by time since diagnosis except for sexual function. The cystectomy group (n = 21) had worse QoL in sexual function, discomfort with sexual intimacy, sexual enjoyment, and male sexual problems than the non-cystectomy group (n = 336). CONCLUSION: Survivors of NMIBC face a unique burden associated with their diagnosis and the often-lifelong surveillance and treatment regimens. The finding has important implications for the design of tailored supportive care interventions to improve QoL for NMIBC survivors.
Authors: Paolo Gontero; Marco Oderda; Anja Mehnert; Alberto Gurioli; Francesco Marson; Ilaria Lucca; Michael Rink; Marianne Schmid; Luis A Kluth; Giovanni Pappagallo; Filippo Sogni; Francesco Sanguedolce; Riccardo Schiavina; Giuseppe Martorana; Shahrokh F Shariat; Felix Chun Journal: J Urol Date: 2013-03-29 Impact factor: 7.450
Authors: Maximilian Burger; James W F Catto; Guido Dalbagni; H Barton Grossman; Harry Herr; Pierre Karakiewicz; Wassim Kassouf; Lambertus A Kiemeney; Carlo La Vecchia; Shahrokh Shariat; Yair Lotan Journal: Eur Urol Date: 2012-07-25 Impact factor: 20.096
Authors: Richard J Sylvester; Adrian P M van der Meijden; Willem Oosterlinck; J Alfred Witjes; Christian Bouffioux; Louis Denis; Donald W W Newling; Karlheinz Kurth Journal: Eur Urol Date: 2006-01-17 Impact factor: 20.096
Authors: Stacy Tessler Lindau; L Philip Schumm; Edward O Laumann; Wendy Levinson; Colm A O'Muircheartaigh; Linda J Waite Journal: N Engl J Med Date: 2007-08-23 Impact factor: 91.245
Authors: N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes Journal: J Natl Cancer Inst Date: 1993-03-03 Impact factor: 13.506
Authors: Madelon N M van der Aa; Milou D Bekker; Theo H van der Kwast; Marie-Louise Essink-Bot; Ewout W Steyerberg; Ellen C Zwarthoff; Fatma E F Sen; Henk W Elzevier Journal: BJU Int Date: 2009-01-14 Impact factor: 5.588
Authors: Ahrang Jung; Matthew E Nielsen; Jamie L Crandell; Mary H Palmer; Ashley Leak Bryant; Sophia K Smith; Deborah K Mayer Journal: Cancer Nurs Date: 2019 May/Jun Impact factor: 2.592
Authors: Marc A Kowalkowski; Aravind Chandrashekar; Gilad E Amiel; Seth P Lerner; Daniela A Wittmann; David M Latini; Heather Honoré Goltz Journal: Sex Med Date: 2014-08 Impact factor: 2.491
Authors: Ahrang Jung; Jamie L Crandell; Matthew E Nielsen; Sophia K Smith; Ashley Leak Bryant; Deborah K Mayer Journal: Support Care Cancer Date: 2022-04-18 Impact factor: 3.603
Authors: Rhyquelle Rhibna Neris; Lucila Castanheira Nascimento; Márcia Maria Fontão Zago Journal: Support Care Cancer Date: 2022-01-11 Impact factor: 3.603
Authors: Claudia Rutherford; Manish I Patel; Margaret-Ann Tait; David P Smith; Daniel S J Costa; Shomik Sengupta; Madeleine T King Journal: Qual Life Res Date: 2020-09-22 Impact factor: 4.147
Authors: Lauren J Lee; Christina S Kwon; Anna Forsythe; Carla M Mamolo; Elizabeth T Masters; Ira A Jacobs Journal: Clinicoecon Outcomes Res Date: 2020-11-23